Judge Limits Discovery Scope in Ozempic Multidistrict Litigation, Excludes Marketing Materials

In a recent decision by Judge Karen Marston, efforts to expand the discovery scope in the ongoing multidistrict litigation (MDL) concerning Ozempic, a diabetes medication, have been curtailed. The plaintiffs had argued for broader discovery, including marketing-related materials, claiming that they were pertinent to the legal issues at hand. Judge Marston, however, determined that marketing discovery was not relevant to the primary legal issues prioritized for early resolution in the court proceedings. This decision underscores the court’s focus on narrowing the scope of discovery to address the central legal questions. For further details on this decision, visit the source.